PET also serves as a translational platform for evaluating novel treatments, quantifying synaptic plasticity, and predicting treatment response
The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimers
Access and Affordability: Getting GLP-1 Without Insurance Requirements Traditional barriers to GLP-1 therapy include insurance denials and membership-based programs
However, this risk in humans is not well established
To validate this structural effect, it will be necessary to use an animal OA rodent model, such as the surgical destabilization of the medial meniscus (DMM), which is a more acceptable and suitable model to study the effects of liraglutide on cartilage degradation 56
This action reduces hunger signals and increases feelings of fullness, naturally limiting calorie intake without requiring constant willpower